World's Best Scientists 2026 revealed!
Maria Debiec-Rychter

Maria Debiec-Rychter

D-Index & Metrics

Genetics

D-Index
78
Citations
19193
World Ranking
1715
National Ranking
25

Maria Debiec-Rychter publication distribution in Genetics in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Genetics in 2026. The highlighted bar marks where Maria Debiec-Rychter sits on this spectrum.

45–54 publications: 6 scientists 55–64 publications: 10 scientists 65–74 publications: 35 scientists 75–84 publications: 84 scientists 85–94 publications: 102 scientists 95–104 publications: 151 scientists 105–114 publications: 175 scientists 115–124 publications: 203 scientists 125–134 publications: 217 scientists 135–144 publications: 205 scientists 145–154 publications: 193 scientists 155–164 publications: 188 scientists 165–174 publications: 170 scientists 175–184 publications: 178 scientists 185–194 publications: 164 scientists 195–204 publications: 173 scientists 205–214 publications: 159 scientists 215–224 publications: 134 scientists 225–234 publications: 143 scientists 235–244 publications: 105 scientists 245–254 publications: 114 scientists 255–264 publications: 92 scientists 265–274 publications: 88 scientists 275–284 publications: 87 scientists 285–294 publications: 80 scientists 295–304 publications: 62 scientists 305–314 publications: 75 scientists 315–324 publications: 67 scientists 325–334 publications: 60 scientists 335–344 publications: 52 scientists 345–354 publications: 40 scientists 355–364 publications: 48 scientists 365–374 publications: 47 scientists 375–384 publications: 46 scientists 385–394 publications: 31 scientists 395–404 publications: 27 scientists 405–414 publications: 40 scientists 415–424 publications: 30 scientists 425–434 publications: 43 scientists 435–444 publications: 29 scientists 445–454 publications: 14 scientists 455–464 publications: 28 scientists 465–474 publications: 21 scientists 475–484 publications: 21 scientists 485–494 publications: 22 scientists 495–504 publications: 17 scientists 505–514 publications: 12 scientists 515–524 publications: 11 scientists 525–534 publications: 8 scientists 535–544 publications: 8 scientists 545–554 publications: 14 scientists 555–564 publications: 4 scientists 565–574 publications: 11 scientists 575–584 publications: 5 scientists 585–594 publications: 11 scientists 595–604 publications: 12 scientists 605–614 publications: 7 scientists 615–624 publications: 6 scientists 625–634 publications: 10 scientists 635–644 publications: 9 scientists 645–654 publications: 10 scientists 655–664 publications: 6 scientists 665–674 publications: 6 scientists 675–684 publications: 6 scientists 685–694 publications: 4 scientists 695–702 publications: 6 scientists 703+ publications: 100 scientists
45 publications 703+

This scientist: 383 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 703 publications or more.

Maria Debiec-Rychter D-index placement in Genetics in 2026

The chart shows the D-index (discipline H-index) distribution of Genetics scientists ranked by Research.com in 2026. The highlighted bar marks where Maria Debiec-Rychter sits on this spectrum.

40–41 D-Index: 24 scientists 42–43 D-Index: 52 scientists 44–45 D-Index: 84 scientists 46–47 D-Index: 112 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 141 scientists 52–53 D-Index: 143 scientists 54–55 D-Index: 145 scientists 56–57 D-Index: 179 scientists 58–59 D-Index: 162 scientists 60–61 D-Index: 175 scientists 62–63 D-Index: 191 scientists 64–65 D-Index: 172 scientists 66–67 D-Index: 184 scientists 68–69 D-Index: 164 scientists 70–71 D-Index: 158 scientists 72–73 D-Index: 150 scientists 74–75 D-Index: 136 scientists 76–77 D-Index: 127 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 111 scientists 82–83 D-Index: 110 scientists 84–85 D-Index: 110 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 102 scientists 90–91 D-Index: 66 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 70 scientists 96–97 D-Index: 54 scientists 98–99 D-Index: 60 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 55 scientists 104–105 D-Index: 45 scientists 106–107 D-Index: 42 scientists 108–109 D-Index: 28 scientists 110–111 D-Index: 39 scientists 112–113 D-Index: 25 scientists 114–115 D-Index: 31 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 34 scientists 120–121 D-Index: 29 scientists 122–123 D-Index: 29 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 27 scientists 128–129 D-Index: 22 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 11 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 21 scientists 140–141 D-Index: 4 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 14 scientists 146–147 D-Index: 6 scientists 148–149 D-Index: 10 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 9 scientists 154–155 D-Index: 8 scientists 156–157 D-Index: 8 scientists 158–159 D-Index: 9 scientists 160+ D-Index: 96 scientists
40 D-Index 160+

This scientist: 78 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 160 D-Index or more.

Overview

Maria Debiec-Rychter is affiliated with KU Leuven in Belgium and specializes in medicine with a focus on oncology and related disciplines. Their research encompasses several main fields including pulmonary and respiratory medicine, rheumatology, oncology, gastroenterology, and surgery. The scientist's subfields reflect a cross-disciplinary approach, emphasizing both clinical and molecular aspects of cancer and related diseases.

Their work covers a variety of topics, highlighting a broad interest in the biology and treatment of tumors along with related diagnostic and genomics challenges. Key research topics include:

  • Sarcoma diagnosis and treatment
  • Gastrointestinal tumor research and treatment
  • Soft tissue tumor case studies
  • Cancer genomics and diagnostics
  • Vascular tumors and angiosarcomas
  • IgG4-related and inflammatory diseases
  • Cardiac tumors and thrombi

Among the publication venues frequently selected by Maria Debiec-Rychter are:

  • Cancer Research
  • International Journal of Molecular Sciences
  • Gastrointestinal Stromal Tumor
  • European Journal of Cancer
  • Genes Chromosomes and Cancer

The scientist has collaborated repeatedly with several coauthors, including:

  • Raf Sciot
  • Patrick Schöffski
  • Agnieszka Woźniak
  • Che-Jui Lee
  • Piotr Rutkowski

Several recent papers define current research directions. These include:

  • "Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE," 2021, European Journal of Cancer
  • "Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor," 2020, Genes Chromosomes and Cancer
  • "Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors," 2020, Translational Oncology
  • "Loss of 9p21 Regulatory Hub Promotes Kidney Cancer Progression by Upregulating HOXB13," 2021, Molecular Cancer Research
  • "Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells," 2020, Scientific Reports

Best Publications

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Toward Minimal Residual Disease-Directed Therapy in Melanoma.

    Florian Rambow;Aljosja Rogiers;Oskar Marin-Bejar;Sara Aibar

  • Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

    Maria Debiec-Rychter;Jan Cools;Herlinde Dumez;Raf Sciot

  • Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

    Grant A. McArthur;George D. Demetri;Allan van Oosterom;Michael C. Heinrich

  • Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

    M. Debiec-Rychter;H. Dumez;I. Judson;B. Wasag

  • Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials

    Piotr Rutkowski;Martine Van Glabbeke;Cathryn J Rankin;Wlodzimierz Ruka

  • PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).

    Pedram Argani;Cristina R Antonescu;Jérôme Couturier;Jean-Christophe Fournet

  • Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma

    Munir R. Tanas;Andrea Sboner;Andre M. Oliveira;Michele R. Erickson-Johnson

  • Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

    Hans Prenen;Jan Cools;Nicole Mentens;Cedric Folens

  • Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor

    Piotr Rutkowski;Zbigniew I. Nowecki;Wanda Michej;Maria Dębiec-Rychter

  • Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor

    Arezoo Mohajeri;Johnbosco Tayebwa;Anna Collin;Jenny Nilsson

  • The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor.

    Cheng-Han Lee;Adrian Mariño-Enriquez;Wenbin Ou;Meijun Zhu

  • Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity

    Maria Debiec-Rychter;Bartosz Wasag;Michel Stul;Ivo De Wever

  • Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients

    Ophélia Maertens;Hans Prenen;Maria Debiec-Rychter;Agnieszka Wozniak

  • 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma

    Cheng-Han Lee;Wen-Bin Ou;Adrian Mariño-Enriquez;Meijun Zhu

  • Atypical Neurofibromas in Neurofibromatosis Type 1 Are Premalignant Tumors

    Eline Beert;Hilde Brems;Bruno Daniëls;Ivo De Wever

  • Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors

    Michael C Heinrich;Diana J Griffith;Arin McKinley;Janice Patterson

  • Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases

    Jerzy Lasota;Christopher L. Corless;Michael C. Heinrich;Maria Debiec-Rychter

  • Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)

    Anu Gupta;Srirupa Roy;Alexander J.F. Lazar;Wei Lien Wang

Frequent Co-Authors

Raf Sciot
Raf Sciot KU Leuven
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
Jan Cools
Jan Cools KU Leuven
Patrick Pauwels
Patrick Pauwels University of Antwerp

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Genetics, there are several related online degrees and career options in healthcare and life sciences worth exploring. Many students combine genetics studies with nursing, healthcare administration, or specialized medical roles to broaden their professional opportunities.

For those considering nursing, some nursing programs that don't require teas or HESI exams make entry into the field more accessible. Alternatively, fast-track programs like the shortest lpn program can help you start your healthcare career quickly.

For advanced or administrative roles, pursuing a graduate degree can be a smart step. Look into the cheapest master's in healthcare administration programs to gain leadership skills affordably. Ambitious professionals may also consider enrolling in nursing phd programs for high-level research and academic careers.

Connecting a background in genetics with these pathways opens doors in research, patient care, hospital administration, and policy work, expanding your options across the growing healthcare sector.

Best Scientists Citing Maria Debiec-Rychter

Trending Scientists

Recently Published Articles